cas 901188-04-3|| where to buy 5,7-difluoro-2-(4-fluorophenyl)-1H-indole

Nombre del producto:5,7-difluoro-2-(4-fluorophenyl)-1H-indole

IUPAC Name:5,7-difluoro-2-(4-fluorophenyl)-1H-indole

Unidad de embalaje	Stock disponible	Precio($)
CM1018063-100mg	in stock	Ţǯư
CM1018063-250mg	in stock	Ƅƞư
CM1018063-500mg	in stock	ƞưŢ
CM1018063-1g	in stock	Ȁưư
CM1018063-5g	in stock	ŢǕưư
CM1018063-10g	in stock	źưưư

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 901188-04-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :901188-04-3; Fórmula molecular:C14H8F3N; Punto de fusión:-; Código de sonrisas:FC1=CC=C(C=C1)C1=CC2=C(N1)C(F)=CC(F)=C2; Densidad:

: Número de catálogo:CM1018063; Peso molecular:247.22; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: VX-147; Vertex Pharmaceuticals announced that inaxaplin (VX-147) , a first-in-class molecule has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD. In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.